SERPINA3 and metabolic dysfunction-associated steatohepatitis: Future studies should focus on developing specific KCTD17 inhibitors and advancing the clinical translation of SERPINA3-basaed therapies, which could provide a novel and effective treatment approach for liver fibrosis in patients with MASH.